Mirabegron Lysosomal pH Modulation for AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), particularly the atrophic form, lack effective molecules that can restore lysosomal activity in retinal pigment epithelium cells to break down photoreceptor outer segments, leading to accumulation of lipofuscin and progressive vision loss.
Innovation Solution
The use of mirabegron, an adrenergic receptor agonist, which lowers lysosomal pH and restores cathepsin D activity, thereby reducing lipofuscin accumulation in retinal pigment epithelium cells, offering a potential therapeutic approach for AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If beta-adrenergic receptor agonists are used to lower lysosomal pH, then lysosomal pH is reduced, but photoreceptor outer segment digestion is not induced
Solution Approach 1:
The patent applies parameter changes by specifically selecting mirabegron, a beta-3 adrenergic receptor agonist, which uniquely combines the ability to lower lysosomal pH with the ability to induce photoreceptor outer segment digestion. This represents a precise parameter optimization within the beta-adrenergic agonist class, identifying the specific molecular structure and receptor selectivity (beta-3 vs beta-1/beta-2) that achieves both required effects simultaneously.
2Quantity of substance
If adrenergic receptor agonists are used to reduce lipofuscin accumulation, then lipofuscin accumulation is reduced, but the mechanism must be specifically targeted to restore lysosomal activity
Solution Approach 1:
The patent uses lysosomal pH as an intermediary parameter. Mirabegron acts on beta-3 adrenergic receptors, which triggers a signaling cascade that ultimately lowers lysosomal pH. This pH reduction serves as the intermediary mechanism that activates cathepsin D and other lysosomal enzymes, thereby enabling photoreceptor outer segment digestion and lipofuscin clearance. The intermediary pH change connects the receptor activation to the final digestive function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mirabegron significantly reduces lipofuscin accumulation and restores lysosomal enzyme activity, demonstrating therapeutic potential for treating AMD by improving photoreceptor outer segment digestion.
Implementation Method 1
mirabegron, an adrenergic receptor agonist, which lowers lysosomal pH
Implementation Method 2
restores cathepsin D activity, thereby reducing lipofuscin accumulation
Data Source
AI summary
Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.